TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$350 Million

Spark Therapeutics

Follow-on Offering

Bookrunner, August 2017

Spark Therapeutics
Spark is a leader in the field of gene therapy, seeking to transform the lives of patients suffering from debilitating genetic diseases by developing one-time, life-altering treatments. The goal of gene therapy is to overcome the effects of a malfunctioning, disease-causing gene. The Company's product candidates have the potential to provide long-lasting effects, dramatically and positively changing the lives of patients with conditions where no, or only palliative, therapies exist. Spark's initial focus is on treating orphan diseases and the Company has built a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases.